Targeting PD-L1 and PD-1, which mediate the Treg-tumor interaction leading to Treg proliferation, has been an active area of research, and there are currently six monoclonal antibodies targeting either PD-L1 or PD-1 that have shown anti-tumor efficacy in more than twenty cancer types (52). The gene discussed is CD274; the disease is neoplasm.